重庆西山科技股份有限公司 投资者关系管理制度 第一章 总则 第一条 为了规范重庆西山科技股份有限公司（以下简称"公司"）的投资者 关系管理工作，进一步加强与投资者之间的信息沟通，完善公司治理结构，切实 保护投资者特别是社会公众投资者的合法权益，促进公司与投资者之间建立长期、 稳定的良好关系，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 海证券交易所上市公司自律监管指引第2号——信息披露事务管理》《上市公司 投资者关系管理工作指引》和《重庆西山科技股份有限公司章程》（以下简称"《公 司章程》"）及其他相关规定，特制定本制度。 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互动 交流和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资者对 公司的了解和认同，提升公司治理水平和企业整体价值，实现尊重投资者、回报 投资者、保护投资者目的的相关活动。 第三条 公司开展投资者关系管理工作应体现公平、公正、公开、客观原则， 平等对待全体投资者，客观、真实、准确、完整地介绍和反映公司的实际状况， 避免过度宣传可能给投资者造成的误导，保障所有投资者享有知情权及其他合法 权益。 第四条 投资 ...

重庆西山科技股份有限公司 募集资金管理制度 第一章 总则 第一条 为规范重庆西山科技股份有限公司（以下简称"公司"）募集资金管 理，提高募集资金使用效率，依照《公司法》、《证券法》、《首次公开发行股票 注册管理办法》、《上市公司证券发行注册管理办法》、《上海证券交易所科创板 上市公司自律监管指引第 1 号—规范运作》、《监管规则适用指引——发行类第 7 号》、《上海证券交易所科创板股票上市规则》、中国证监会《上市公司募集资金 监管规则》等法律、法规和规范性文件，以及《公司章程》的规定，特制定本制度。 第二条 本制度所称募集资金是指公司通过发行股票或者其他具有股权性质的 证券，向投资者募集并用于特定用途的资金，但不包括公司实施股权激励计划募集 的资金。超募资金是指实际募集资金净额超过计划募集资金金额的部分。 第三条 公司应当建立并完善募集资金存放、管理、使用、改变用途、监督和 责任追究的内部控制制度，明确募集资金使用的分级审批权限、决策程序、风险控 制措施及信息披露要求。公司董事会应当持续关注募集资金存放、管理和使用情况， 有效防范投资风险，提高募集资金使用效益。 第五条 公司控股股东、实际控制人及其他关联人不 ...

第二条 独立董事是指不在公司担任除董事外的其他职务，并与其所受聘的 公司及其主要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影 响其进行独立客观判断关系的董事。 重庆西山科技股份有限公司 独立董事工作制度 第一章 总 则 第一条 为进一步完善重庆西山科技股份有限公司（以下简称"公司"或"本 公司"）的法人治理机构，改善董事会结构，强化对内部董事及经理层的约束和 监督机制，保护中小股东及债权人的利益，促进公司的规范运作，根据中国证券 监督管理委员会（以下简称"中国证监会"）颁布的《上市公司独立董事管理办 法》、《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上 海证券交易所科创板上市公司自律监管指引第1号--规范运作》以及《重庆西山 科技股份有限公司章程》（以下简称"《公司章程》"）等有关规定，并结合公 司实际，特制定本制度。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务。独立董事应当按 照相关法律法规、《公司章程》和本工作制度的要求，认真履行职责，在董事会 中发挥参与决策、监督制衡、专业咨询作用，维护公司整体利益，保护中小股东 的合法权益不受损害。独立董事应当独立履行职责，不受 ...

Group 1 - The core viewpoint of the article highlights that Xishan Technology (SH 688576) reported its Q3 performance, showing a revenue increase but a significant decline in net profit [1] - For the first three quarters of 2025, the company's revenue was approximately 231 million yuan, representing a year-on-year increase of 11.32% [1] - The net profit attributable to shareholders of the listed company was around 43.4 million yuan, reflecting a year-on-year decrease of 34.14% [1] Group 2 - As of the report, Xishan Technology has a market capitalization of 3 billion yuan [2]

Financial Performance - The company's operating revenue for the third quarter reached ¥75,764,802.05, an increase of 35.45% compared to the same period last year[4]. - The total profit for the year-to-date period decreased by 37.79% to ¥44,257,163.93, primarily due to a decline in product gross margins following the inclusion of a product in centralized procurement[4][10]. - The net profit attributable to shareholders for the third quarter was ¥9,013,010.27, reflecting a year-on-year increase of 28.75[4]. - The basic earnings per share for the third quarter was ¥0.20, up 42.86% from the previous year[5]. - The net profit for the first three quarters of 2025 was ¥43,395,010.59, down 34.1% from ¥65,894,756.22 in the first three quarters of 2024[23]. - The basic earnings per share for the first three quarters of 2025 was ¥0.96, down from ¥1.28 in the same period of 2024[23]. Research and Development - Research and development expenses totaled ¥14,701,698.65 for the quarter, accounting for 19.40% of operating revenue, a decrease of 5.54 percentage points year-on-year[5]. - Research and development expenses increased to ¥39,443,550.90 in 2025, compared to ¥36,961,012.42 in 2024, reflecting a focus on innovation[22]. - The company successfully obtained CE-MDR certification for its neurosurgery, orthopedics, ENT, and breast surgery power device products during the reporting period, positively impacting future international product access and sales[15]. - The company added 112 new patents in 2025, bringing the total to 1,368 valid patents, including 768 for surgical power devices, 243 for endoscopes, and 263 for energy surgical equipment, indicating continuous technological innovation[15]. - The company’s ENT DK-ENT-MS2 and neurosurgery DK-N-MS2 surgical power devices completed R&D and production, significantly enhancing product competitiveness and market recognition[15]. - The company’s endoscope-related products made significant technical progress, including the successful registration of the endoscope fluorescence imaging system and optimization of image algorithms for the 4K endoscope system[16]. Sales and Market Performance - The company reported a significant increase in sales of orthopedic products, with revenue from this segment rising from 24% to 35% of total operating revenue[10]. - The revenue from consumables increased significantly, with a cumulative growth of over 180% during the reporting period for ultrasonic bone tissue surgical equipment[15]. - Sales of single-use breast biopsy needles increased by 45% compared to the same period last year, enhancing brand influence and market position[17]. - The company’s breast surgery consumables experienced increased demand due to price reductions from centralized procurement policies, leading to a significant rise in surgical volumes[16]. - The company achieved breakthroughs in the number of plasma devices and consumables entering hospitals in several provinces, including Shanxi, Anhui, Guangdong, Shaanxi, Gansu, Ningxia, and Chongqing[15]. Assets and Liabilities - The total assets of the company as of the end of the reporting period were ¥1,869,898,817.92, a decrease of 2.90% from the end of the previous year[5]. - The total assets as of September 30, 2025, were ¥1,869,898,817.92, a slight decrease from ¥1,925,782,570.99 at the end of 2024[20]. - The total liabilities decreased to ¥151,597,332.96 from ¥160,751,904.23, showing a reduction in financial obligations[20]. - The company's inventory increased to ¥102,037,336.91 from ¥75,332,518.62, suggesting a buildup of stock[18]. Cash Flow and Financial Activities - Cash flow from operating activities for the year-to-date period improved significantly, with a net cash flow of ¥51,162,209.23, an increase of 215% compared to the previous year[4][10]. - The net cash flow from operating activities for the first nine months was $51.16 million, a significant improvement from a net outflow of $44.49 million in the same period last year[27]. - The company's cash and cash equivalents decreased to ¥265,314,061.07 from ¥558,452,319.69 at the end of 2024, indicating a potential liquidity concern[18]. - The company's financial expenses showed a slight improvement, with a net financial cost of -¥10,362,319.90 compared to -¥10,926,273.37 in the previous year[22]. - The company reported a significant increase in contract liabilities to ¥22,743,472.11 from ¥7,869,652.39, indicating growth in customer commitments[20]. - Total cash inflow from investment activities decreased to $1.19 billion, down from $1.47 billion year-over-year[27]. - The net cash flow from investment activities was negative at -$250.93 million, compared to a positive $37.74 million in the previous year[27]. - Cash outflows from financing activities totaled $93.26 million, a decrease from $439.25 million in the same period last year[27]. - The ending cash and cash equivalents balance was $265.31 million, slightly down from $266.28 million year-over-year[28]. - The company received $1.18 billion from the recovery of investments, compared to $1.45 billion in the previous year[27]. - Cash paid for the acquisition of fixed assets and other long-term assets was $78.76 million, down from $131.53 million year-over-year[27]. - The company paid $46.06 million in dividends and interest, a slight decrease from $48.90 million in the previous year[27]. - The cash flow from operating activities totaled $300.75 million, an increase from $206.73 million year-over-year[27]. - The company reported a total cash outflow of $293.14 million for the period, compared to $445.97 million in the same period last year[27].

证券代码：688576 证券简称：西山科技 公告编号：2025-042 重庆西山科技股份有限公司 关于取消监事会、修订《公司章程》并办理工商变更 登记及制定、修订部分治理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重庆西山科技股份有限公司（以下简称"公司"）于 2025 年 10 月 30 日召开 了第四届董事会第八次会议，审议通过了《关于取消监事会及修订<公司章程> 的议案》《关于修订及制定公司部分治理制度的议案》。公司于同日召开第四届监 事会第八次会议，审议通过了《关于取消监事会及修订<公司章程>的议案》，上 述议案尚需提交公司股东大会审议。具体情况如下： 一、关于取消监事会 根据 2024 年 7 月 1 日起实施的《中华人民共和国公司法》（以下简称"《公 司法》"）及中国证券监督管理委员会（以下简称"中国证监会"）于 2024 年 12 月 27 日发布的《关于新<公司法>配套制度规则实施相关过渡期安排》等相关 法律法规的规定，并结合公司实际情况，公司不再设置监事会，由董事会审计委 员会行使《公司法 ...

公司于 2025 年 10 月 30 日召开了第四届董事会第八次会议，审议通过了《关 于补选公司第四届董事会非独立董事的议案》，同意提名岳瀚先生为公司第四届 董事会非独立董事候选人，任期自公司股东大会审议通过之日起至第四届董事会 任期届满之日止。 岳瀚先生的个人简历详见附件。上述议案尚需提交公司股东大会审议。 证券代码：688576 证券简称：西山科技 公告编号：2025-043 重庆西山科技股份有限公司 关于补选公司非独立董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《公司法》《公司章程》等相关规定，董事会提名委员会对第四届董事 会非独立董事候选人岳瀚先生的任职资格审查，同意提名岳瀚先生为公司第四届 董事会非独立董事候选人。 岳瀚先生个人简历 岳瀚，男，汉族，1989 年 1 月生，2010 年 7 月参加工作，硕士研究生学历。 2010 年 7 月至 2016 年 8 月任天津银行北京分行投资部经理，2018 年 3 月至 2020 年 9 月任启迪未来投资控股（北京）有限公司医疗事业部总经理助理，2 ...

Core Viewpoint - Xishan Technology (688576) has experienced a slight decline in stock price, with a current market capitalization of 2.952 billion yuan, ranking 110th in the medical device sector and 4486th in the A-share market [1] Shareholder Changes - As of September 19, 2025, the number of shareholders decreased by 3.33% to 5284, with the average shareholding increasing from 8324 shares to 8611 shares, and the average shareholding value reaching 566,200 yuan [2][4] Institutional Research Highlights - The company has established a clear plan for overseas market expansion, with products currently covering 46 countries and regions, focusing on Southeast Asia, Latin America, and countries along the Belt and Road Initiative [3][4] - The company is seeking partnerships with international medical device giants as part of its strategy for overseas market expansion, enhancing market access and distribution networks [3] - The company is considering expanding into the surgical robot field and will continue to monitor the feasibility of brain-computer interface technology [3][4] - In the first half of 2025, the company achieved revenue of 155.0358 million yuan, reflecting a year-on-year growth of 2.40%, with ongoing efforts to promote disposable consumables and expand endoscope products [3][4]

Group 1 - On September 23, Xishan Technology's stock fell by 1.44%, with a trading volume of 23.32 million yuan [1] - The financing data on the same day showed a financing purchase amount of 4.07 million yuan and a net financing purchase of 2.27 million yuan, with a total financing and securities balance of 93.61 million yuan, accounting for 6.68% of the circulating market value [1] - The company specializes in the research, production, and sales of surgical power devices, with 92.10% of its main business revenue coming from this segment [1] Group 2 - As of September 19, the number of shareholders of Xishan Technology was 5,284, a decrease of 3.33%, while the average circulating shares per person increased by 3.44% [2] - For the first half of 2025, Xishan Technology achieved an operating income of 155 million yuan, a year-on-year increase of 2.40%, but the net profit attributable to the parent company decreased by 41.62% to 34.38 million yuan [2] Group 3 - Since its A-share listing, Xishan Technology has distributed a total of 94.07 million yuan in dividends [3]

Group 1 - The board of directors of Chongqing Xishan Technology Co., Ltd. received a resignation report from director Zhang Weiya, who is resigning due to work relocation [1] - Zhang Weiya's resignation does not result in the board's member count falling below the legal minimum and will not affect the normal operation of the board [1] - Zhang Weiya did not hold any shares in the company during her tenure and has positively contributed to the company's governance [1] Group 2 - The company expresses gratitude for Zhang Weiya's contributions during her time as a director [1]